Alibaba Health Information Technology Limited
0241.HK
Hong Kong Stock Exchange3.47
HKD
+0.07
- -
Alibaba Health Information Technology Limited
0241.HK
(Hong Kong Stock Exchange)
Recent
price
3.47
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Alibaba Health Information Technology Limited engages primarily in providing integrated healthcare information and digital health services in China. Its core products and services include pharmaceutical e-commerce, online medical and healthcare services such as medical consultations, appointment booking, vaccination, dental and mental care, optometry, nursing services, and traditional Chinese medicines. The company operates through multiple online platforms including Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark, serving both business-to-consumer and business-to-business customers. Alibaba Health also provides health management solutions, chronic disease management, health insurance products, digital tracking services, and operates internet hospitals supported by cloud-based infrastructure. Founded in 1998 and headquartered in Causeway Bay, Hong Kong, Alibaba Health is a subsidiary and the flagship healthcare platform of Alibaba Group. Its business model capitalizes on e-commerce, big data, AI technology, and cloud computing, aiming to provide affordable, convenient, and efficient healthcare solutions to hundreds of millions of families through a seamless integration of online and offline healthcare resources. Recently, Alibaba Health completed a major strategic acquisition by securing the rights to certain services related to Alibaba Group’s marketing platform, Alimama, in a deal valued at HK$13.51 billion (approximately US$1.73 billion). This transaction, announced in late 2023, is intended to enhance Alibaba Health’s revenue growth and profitability outlook while improving service capabilities for online retailers. Additionally, in August 2025, the company entered into a strategic cooperation agreement with Innovent Biologics to collaborate on post-diagnosis disease management, supply chain, and digital marketing initiatives. It also acquired Hangzhou Jingzhun Health Information Technology Co., Ltd. from Alibaba Group for HK$13.5 billion to expand its healthcare services. These moves reflect Alibaba Health's focused expansion and deepening integration of pharmaceutical services, medical technology, and digital healthcare offerings. Alibaba Health operates within the pharmaceutical and healthcare sectors, targeting a broad customer base that includes individual consumers, healthcare providers, and pharmaceutical companies across China. It remains highly reliant on its e-commerce platform businesses, which accounted for about 93% of revenue in recent years, and holds a leading market share in China's pharmaceutical e-commerce sector by gross merchandise volume. The company continues to develop its digital healthcare ecosystem emphasizing AI technology integration for intelligent healthcare management. Overall, Alibaba Health Information Technology Limited stands as a comprehensive digital healthcare service provider leveraging Alibaba Group’s technological ecosystem to deliver a wide range of pharmaceutical products, online and offline healthcare services, health management solutions, and digital marketing innovations for the healthcare industry.
Trip.com Group Limited Reports Unaudited Fourth Quarter and Full Year of 2025 Financial Results